Defence’s Accum technology With ADC And radiopharmaceutical programs target cancer

CAR-T Digest - August 2020

14 July 2025: Defence’s Accum technology with ADC and radiopharmaceutical programs target cancer

Defence Therapeutics is advancing its Accum-based ADC and radiopharmaceutical programs, showing superior intracellular delivery and cytotoxicity in preclinical cancer models compared to conventional ADCs
The company is collaborating with other ADC firms to validate the added efficacy of its Accum technology, aiming to attract licensing and co-development deals
Radiopharmaceutical studies, conducted with Canadian Nuclear Laboratories, include biodistribution, pharmacokinetics, and therapeutic assessments using Accum–radiolabelled antibodies
Defence is optimizing its Accum platform while monitoring global market growth, with the ADC market expected to reach $29.9B and the radiopharmaceutical market $16.8B by 2034 and 2033 respectively